neuroendocrine carcinoma epidemiology forecast

Neuroendocrine Carcinoma (NEC) Insights and Trends

• NEC represents the high-grade end of the neuroendocrine neoplasm (NEN) spectrum and is characterized by poorly differentiated tumor morphology, rapid progression, and a high proliferative index. This report focuses specifically on extrapulmonary NEC, excluding all pulmonary forms. By limiting the scope to non-pulmonary cases, it provides a clearer and more targeted analysis of disease characteristics, trends, and clinical treatment insights.
• In 2025, the total number of incident cases of NEC across the 7MM was estimated at approximately 20,000. This figure is expected to increase, driven by advancements in pathological evaluation and growing clinical awareness of high-grade neuroendocrine malignancies.
• According to DelveInsight’s analysis, in 2025, the US reported approximately 30,000 incident cases of neuroendocrine neoplasms (NEN), including around 9,000 cases of NEC, reflecting a notable proportion of aggressive malignancies within the broader NEN landscape, with nearly 950 cases attributed to extrapulmonary NEC.
• Wider utilization of advanced imaging modalities and specialized pathology services is improving the detection and clinical characterization of NEC, enabling more accurate confirmation of neuroendocrine differentiation and disease staging.
• Despite ongoing research efforts, NEC remains associated with major clinical challenges, including aggressive tumor biology, frequent late-stage diagnosis and high mortality.

DelveInsight's ‘Neuroendocrine Carcinoma (NEC) –Epidemiology Forecast – 2036’ report delivers an in-depth understanding of NEC, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Geography Covered

• North America: The United States
• Europe: Germany, France, Italy, Spain and the United Kingdom
• Asia-Pacific: Japan

Neuroendocrine Carcinoma (NEC) - Understanding

NEC Overview and Diagnosis

NEC a rare and highly aggressive malignancy that arises from neuroendocrine cells, which are specialized cells possessing characteristics of both nerve cells and hormone-producing endocrine cells. These cells are widely distributed throughout the body, particularly in organs such as the lungs, gastrointestinal tract, pancreas, and other endocrine tissues. Genetic and molecular alterations within neuroendocrine cells may disrupt normal cellular regulation, resulting in uncontrolled proliferation, tumor formation, and the potential for local invasion and distant metastasis.

Diagnosis of NEC involves a comprehensive and multidisciplinary evaluation that combines clinical assessment, radiologic imaging, and histopathological confirmation. Because NEC often presents with non-specific clinical manifestations and can arise in several organs such as the lung, gastrointestinal tract, pancreas, and other neuroendocrine tissues, establishing an accurate diagnosis requires careful integration of clinical findings, imaging results, and tissue-based pathological examination. The aggressive nature of NEC, which is characterized by rapid tumor growth, early metastatic spread, and high proliferative activity, makes early and accurate identification particularly important for understanding disease progression and biological behavior.

Further details are provided in the report.

Neuroendocrine Carcinoma (NEC) Epidemiology

Key Findings from NEC Epidemiological Analysis and Forecast

• In 2025, the total number of incident cases of extrapulmonary NEC in the United States was approximately 950 cases and is projected to increase by 2036, reflecting gradual changes in disease detection and reporting.
• In 2025, the number of incident cases of extrapulmonary NEC across EU4 and the UK was approximately 620, with UK accounting for the largest share of approximately 270 cases.
• In EU4 and the UK, the extrapulmonary NEC burden in 2025 was supported by a considerable number of cases, driven by improved diagnostic capabilities, increased awareness of rare neuroendocrine malignancies, and broader access to specialized oncology services. The highest proportion of cases was observed in Stage IV, accounting for approximately 34% of total cases in 2025.
• In 2025, Japan reported nearly 7,500 total incident cases of NENs and approximately 4,000 incident cases of NEC, reflecting a measurable burden of these heterogeneous tumors within the country.
• In Japan, extrapulmonary NEC burden in 2025 showed a higher occurrence of small-cell histology with approximately 280 cases compared with large-cell NEC with around 130 cases. This distribution highlights the predominance of the small-cell subtype within the NEC histological spectrum in the region.

Industry Experts and Physician Views for Neuroendocrine Carcinoma (NEC)

To keep up with NEC dynamic epidemiology trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the NEC epidemiology, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 8+ KOLs to gather insights at country level. Centers such as the Emory University, Case Western Reserve University, Stanford University, University Hospital of Giessen etc. were contacted. Their opinion helps understand, validate, highlight and provide epidemiological context in NEC.

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of NEC, explaining their causes, signs and symptoms and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along diagnostic guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Report Insights

• NEC Patient Population Forecast
• Country-wise Epidemiology Distribution
• Total Incident Cases of NEN
• Total Incident Cases of NEC
• Total Incident Cases of Extrapulmonary NEC
• Stage-specific Cases of Extrapulmonary NEC
• Site-specific Cases of Extrapulmonary NEC
• Gender-specific Cases of Extrapulmonary NEC
• Histology-specific Cases of Extrapulmonary NEC

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• 11-year forecast
• Patient Burden Trends (by geography)
• The 7MM Coverage

FAQs

Epidemiology Insights

• What is the forecast period covered in the report?
• How is epidemiological data collected and analyzed for forecasting purposes?
• Out of all EU4 countries and the UK, which country had the highest population of NEC cases?
• What are the disease risks and burdens of NEC?
• At what compound annual growth rate the population is expected to grow across the 7MM during the forecast period?
• What would be the forecasted patient population of NEC at the 7MM level?

Reasons to Buy

• The report will help in developing business strategies by understanding the latest epidemiology trends.
• Insights on patient burden/incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand KOLs’ perspectives on the dynamic epidemiology trends.
• This Artificial Intelligence (AI)   enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.